Join to view full profile
UCI Medical Center101 The City Drive SouthOrange, CA 92868
Phone+1 714-456-8978
Dr. Demetriou is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of TorontoNeurology Residency, 1996 - 2001
University of Toronto Faculty of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2001 - 2027
Royal College of Physicians and Surgeons of Canada Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2015-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2015-2017
Publications & Presentations
PubMed
- Acute effects of high-dose corticosteroids on serum biomarker profiles in primary CNS demyelinating disease: A pilot study.Anastasia P Chumakova, Michael Demetriou, Michael Sy
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2026-09-07 - Neurogenic Lower Urinary Tract Dysfunction in Women With Multiple Sclerosis.Kruti Patel, Amy Yan, Alejandra Cacheiro, Michael Sy, Michael Demetriou
Urogynecology. 2026-04-30 - 1 citationsBAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab.Anastasia Chumakova, Lauren McKay, Victoria Fleming, Michael Demetriou, Michael Sy
Journal of Neuroinflammation. 2025-11-28
Press Mentions
New Immunotherapy Approach Hits the Sweet Spot with Solid TumorsOctober 15th, 2025- Pan-Cancer Immunotherapy Avoids Healthy Tissue by Targeting GlycansSeptember 26th, 2025
- New Universal Therapy Effective in Multiple Tumor TypesSeptember 25th, 2025
Grant Support
- Institute for Clinical and Translational Science NRSA Postdoctoral Research Training CoreUNIVERSITY OF CALIFORNIA-IRVINE2025–2030
- Maximizing GlyTR pan-cancer immunotherapy by enhancing target densityGLYTR THERAPEUTICS, INC.2025–2028
- Oral N-Acetylglucosamine as Anti-Neuroinflammatory Add-on therapy for Multiple Sclerosis (NANA-MS)UNIVERSITY OF CALIFORNIA-IRVINE2025–2026
- Extended half-life GlyTR1 combined with checkpoint blockade for Cancer ImmunotherapyGLYTR THERAPEUTICS, INC.2023–2026
- Institutional Career Development CoreUNIVERSITY OF CALIFORNIA-IRVINE2015–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
